title: [Nutritional assessment and quality of life of oncology outpatients initiating treatment with tyrosine‑kinase inhibitors].
abstract: OBJECTIVE
  The consumption of oral antineoplastics -and more particularly of tyrosine-kinase inhibitors (TKI)- has increased in recent years. These therapies show a better tolerance but still, the nutritional alterations related to their daily and chronic clinical use are under investigation. This study assesses the effects of TKI on the intake, nutritional status and micronutrients as well as the patients quality of life.
  
  
  METHODS
  A prospective longitudinal study was conducted including adult patients having started some TKI treatment from July 2012 to June 2013, and a 6 month follow-up period was established. Demographic pharmacotherapeutic, nutritional and biochemical variables were collected and also a EORTC-QLQ30 questionnaire at baseline, first, third and sixth month of treatment.
  
  
  RESULTS
  31 patients were included in the study. The percentage of weight loss at treatment baseline was statistically matched to the results on the patient-generated Global Subjective Assessment. Appetite decreased after one month of treatment, and so did the calorie consumption; 62.1% of the patients lost weight, 55.5% on the third month and 70.6% on the sixth month. 6-17% of the patients suffered from malnutrition to some degree during the follow-up period and a decrease of calcium, phosphate and magnesium plasma levels was detected. The emotional scale was the one with a lowest score in EORTC QLQ-30, and fatigue and lack of appetite were the most common symptoms at treatment baseline, progressively increasing those of nausea, vomits and diarrhea.
  
  
  CONCLUSIONS
  Patients treated with TKI did not show a relevant malnutrition. Considering the results, it is important to take into account weight loss at treatment baseline; it is also important to control calcium and phosphate levels during treatment, to advise and counsel the patient on the GI effects (nausea, vomits and diarrhea) and emotionally reinforce the patient.
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid. Spain. almuribed@hotmail.com.
authors.forename: Almudena
authors.initials: A
authors.lastname: Ribed Sánchez
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid. Spain. rosa.romero@salud.madrid.org.
authors.forename: Rosa María
authors.initials: RM
authors.lastname: Romero-Jiménez
authors.affiliation: Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Madrid. Spain. cuerda.cristina@gmail.com.
authors.forename: Cristina
authors.initials: C
authors.lastname: Cuerda-Compes
authors.affiliation: Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Madrid. Spain. ihiguera@salud.madrid.org.
authors.forename: Isabel
authors.initials: I
authors.lastname: Higuera-Pulgar
authors.affiliation: Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Madrid. Spain. marialuisa.carrascal@salud.madrid.org.
authors.forename: M Luisa
authors.initials: ML
authors.lastname: Carrascal-Fabian
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid. Spain. vicente.escudero@salud.madrid.org.
authors.forename: Vicente
authors.initials: V
authors.lastname: Escudero-Vilaplana
authors.affiliation: Servicio de Oncología. Hospital General Universitario Gregorio Marañón. Madrid. Spain. joseangel.arranz@salud.madrid.org.
authors.forename: Jose Angel
authors.initials: JA
authors.lastname: Arranz-Arija
authors.affiliation: Unidad de Nutrición Clínica y Dietética. Hospital General Universitario Gregorio Marañón. Madrid. Spain. pgarciap@salud.madrid.org.
authors.forename: Pilar
authors.initials: P
authors.lastname: García-Peris
authors.affiliation: Servicio de Farmacia. Hospital General Universitario Gregorio Marañón. Madrid. Spain. maria.sanjurjo@salud.madrid.org.
authors.forename: María
authors.initials: M
authors.lastname: Sanjurjo-Sáez
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008137:Longitudinal Studies; D009369:Neoplasms / Q000188:drug therapy* / Q000523:psychology*; D015596:Nutrition Assessment; D010045:Outpatients; D011446:Prospective Studies; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011788:Quality of Life; D011795:Surveys and Questionnaires; D015431:Weight Loss / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors